Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Leiomyosarcoma

• Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
• Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
• Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
• Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
• Letrozole in Uterine Leiomyosarcoma
• Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
• Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
• A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
• Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma
• Niraparib for the Treatment of Leiomyosarcoma
• Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC
• Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
• ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma
• Lurbinectedin + Doxorubicin In Leiomyosarcoma
• Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
• A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma
• A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
• A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
• Targeting ATR in Soft-tissue Sarcomas
• CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma
• A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
• Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma
• Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
• Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
• Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
• Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
• A Study of LY3435151 in Participants With Solid Tumors
• Surgery With Our Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
• A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors
• FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study
• A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
• A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
• Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors
• A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma
• Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin
• A Study of PTC596 (Unesbulin) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
• M6620 (VX-970) in Selected Solid Tumors
• Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
• Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
• Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment
• Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
• Vorinostat (SAHA) in Uterine Sarcoma
• Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
• A Study of Nivolumab in Selected Uterine Cancer Patients
• Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
• Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
• Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
• Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
• Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
• Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma
• Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
• Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum
• Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
• Pazopanib for Treating Uterine Leiomyosarcoma
• SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
• Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
• Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma
• Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
• Pazopanib vs. Pazopanib Plus Gemcitabine
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
• Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma
• Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
• Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
• A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
• Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
• Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
• Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
• Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
• Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
• Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine
• Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
• Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
• A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
• Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
• Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
• Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
• Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
• Sorafenib and Dacarbazine in Soft Tissue Sarcoma
• Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
• Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
• AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
• Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
• Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
• Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
• Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
• Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
• Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
• Bevacizumab and Radiation Therapy for Sarcomas
• Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
• Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma
• Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
• Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
• Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
• Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
• Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
• Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
• A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
• Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
• Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
• Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
• Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
• Chemotherapy in Treating Patients With Sarcoma of the Uterus
• Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
• Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus
• S9624 Ifosfamide in Treating Patients With Meningeal Tumors
• Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus